Novadoz Pharmaceuticals reported on Tuesday the receipt of the US FDA approval for the generic version of Pregabalin capsules in 25mg, 50mg, 75mg, 100mg, 150mg, 200mg, 225mg and 300mg strength capsules in 90 count bottles, with bulk sizes slated for post launch.
The patent expiration for the brand Lyrica, which is marketed by Pfizer, reportedly overlapped with the day Novadoz began shipping of the product.
According to Novadoz, Pregabalin is indicated for epilepsy, neuropathic pain, fibromyalgia, restless leg syndrome as well as to treat epilepsy as adjunctive therapy for partial seizures.
Currently, the Lyrica brand is trending over USD5.4bn in published annual sales, added the company.
Novadoz Pharmaceuticals is the US based sales & marketing affiliate for MSN Labs, based in Hyderabad India, engaged in the development and manufacturing of API (active pharmaceutical ingredients), KSMs (key starting materials) and product intermediates.
Microbion's lead antimicrobial given generic name Pravibismane
Primex Pharmaceuticals names new global commercial head
JAMA Oncology Publishes Analysis of Patients with Prior Gastrectomy Treated with Lonsurf
Meitheal Pharmaceuticals Launches Heparin Sodium Injection, USP in the United States
Xellia Pharmaceuticals Names Baker as Chief Commercial Officer of Xellia North America
Dr. Reddy's Laboratories Launches Fosaprepitant for Injection in the US Market
US FDA grants SunGen Pharma seventh ANDA approval for Fosapreptant
US FDA grants approval to Novitium Pharma's Biovitrum's Orfadin
Sagent Pharmaceuticals gets FDA clearance for Omega manufacturing site
Novadoz Pharmaceuticals awarded FDA clearance for Fosaprepitant and Decitabine generics
Endo reports FDA approval for first generic Orfadin
Sumitomo Dainippon Pharma to launch atypical antipsychotic LONASEN(R) Tape in Japan